All News

psoriasis.NPF_.png

Is IL-23 Better than IL-17 Inhibition in Psoriasis?

Jack Cush, MD

Data presented at the recent American Academy of Dermatology meeting suggests that interleukin (IL)-23 inhibition with risankizumab was more effective than the IL-17 inhibition (secukinumab) based on a 52 week randomized head-to-head trial in moderate to severe psoriasis patients.

Read Article
podcast logo

RheumNow Podcast – Lupus Mortality Declines, But… (6.26.20)

Jack Cush, MD

Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article
patient.safety.jpg

Adverse Events With Rheum Biologics Rise With Age

RheumNow

Among patients with rheumatic diseases, age and female sex were important factors associated with the development of a first adverse event after initiating biologic treatment, Spanish researchers reported.

Read Article
podcast logo

RheumNow Podcast – Enough Already with Weaning (6.19.20)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
backpain.hip_.jpg (keep)

Cosentyx FDA Approval for Non-Radiographic Axial Spondyloarthritis

Jack Cush, MD

Yesterday the FDA approved secukinumab (Cosentyx) for the treatment of patients with active non-radiographic axial spondyloarthritis (nr-axSpA). There are now three agents that are FDA approved for nr-axSpA: certolizumab, ixekizumab and now, secukinumab. 

Read Article
EULAR 2020 Roundup

Virtual EULAR 2020 Round Up

Jack Cush, MD

In this week's podcast, Drs. Artie Kavanaugh and Jack Cush present highlights from the virtual EULAR2020 meeting held June 3-6, 2020. Featured reports include the SELECT-CHOICE study, the EXCEED trial, Avacopan in AAV, BeST mortality outcomes, BLISS-LN study, biosimilars and tofa in systemic sclerosis.

Read Article
List.jpg (keep)

Day 3 - Top 5 from EULAR 2020

Jack Cush, MD

These were my top abstracts from Thursday, 4th of June at EULAR 2020:

Read Article
List.jpg (keep)

Day 2 – Top 5 from EULAR 2020

Jack Cush, MD

These were my top abstracts from Thursday, 4th of June at EULAR 2020.

Read Article
psoriatic.PIP_.JPG

Are we doing our best treating seronegative arthritides?

Olga Petryna, MD

Every time a big scientific meeting ends I ask myself a question: how is it going to affect the way I treat my patients? This year the question pertains to management of axial spondyloarthropathies and psoriatic arthritis.

Read Article
The CHMP of the European Medicines Agency has recommended the label expansion of IL-17 inhibitor, Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6-18 years. https://t.co/1qYL5ASkrg

Links:

Dr. John Cush RheumNow ( View Tweet)

WHO global safety database shows increased risk of DVT & PE with tofacitinib & baricitinib, who were likely to be older with preexisting VTE risk. In EU, TOFA risk for DVT/PE was OR 2.3; BARI risk was OR 3.4. No VTE risk for BARI in US, TOFA 2.0 VTE risk https://t.co/PUBUzfrydn

Links:

Dr. John Cush RheumNow ( View Tweet)

#EULAR2020 Round-Up w/ Drs. Kavanaugh & Cush. Watch it on RheumNow https://t.co/5v9BTuLrPX or listen to the podcast on iTunes https://t.co/FHJv01AAbC or on Android Sound Cloud https://t.co/nb7iXdRMMb

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is Up! New FDA approvals for secuminumab, canakinumab, risk of GI perforations, tocilizumab in COVID, Weaning DMARDs/Biologics and Blacks with AS. Watch here>> https://t.co/2fTQPJ5iSr Listen to the podcast on Soundcloud>> https://t.co/uPklKQEauE

Links:

Dr. John Cush RheumNow ( View Tweet)

Rheumatology Round-Up from #EULAR2020 w/ Drs. Kavanaugh & Cush. Watch it on RheumNow https://t.co/5v9BTuLrPX or listen to the podcast on iTunes https://t.co/FHJv01AAbC or on Android Sound Cloud https://t.co/nb7iXdRMMb

Links:

Dr. John Cush RheumNow ( View Tweet)

#EULAR2020 #op0054 DISCOVER 1&2 rct results for Guselkumab in PsA w/ sacroiliitis: significantly better BaSDAI, improved spinal pain& ASDAS-CRP vs PBO suggestive of good clincial efficacy. No radiographic data @RheumNow https://t.co/MeXV08hcBU
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 #op0051 presence of Structural Enthrseal Lesions (SEL) in PSO associated w/higher risk of progression to PsA: 37.5%If SEL present vs 3.4% no SEL/no arthalgia& 15.2% no SEL/+arthralgia. Highest risk in PSO w/SEL+arthralgia at 42.8% @RheumNow https://t.co/7knYXeap7l
Olga Petryna DrPetryna ( View Tweet)
How do you approach your PsA patients with suboptimal response to MTX in moderate doses?

Olga Petryna DrPetryna ( View Tweet)

#EULAR2020 #op0050 RCT ph4 results: in inadequately controlled PsA addition of ADA results in better outcomes in terms MDA, ACR20, PASI75, HAQ-DI&LEI as opposed to MTX dose escalation @RheumNow https://t.co/iMgCkRawCl
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 #LB0001 SELECT-PsA-1 Upadacitinib vs PBO vs ADA: UPA 15/30 mg non-inferior &UPA 30 superior to ADA for ACR20. At wk12 ACR 20 70.6% UPA15, 78.5% UPA30 vs 36.2%PBO & 65%ADA. Better ACR50/70 &MDA va PBO. No new safety signals. @RheumNow https://t.co/QZkMdoqXEC
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 #op0079 ASAS-MRI group offers updated definition of the structural lesions in SI joints in AxSpA: -erosion in >=2 consecutive slices or in >=3 SIJ quadrants - fat lesions w/depth >1cm in >=1SIJ quadrant are high priority candidates @RheumNow https://t.co/EU1WWqJ4h3
Olga Petryna DrPetryna ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×